반응식
[CH:1]1([N:4]([CH2:18][C:19]2[O:23][C:22]([C:24](OCC)=[O:25])=[N:21][N:20]=2)[S:5]([C:8]2[C:13]([CH3:14])=[CH:12][C:11]([O:15][CH3:16])=[CH:10][C:9]=2[CH3:17])(=[O:7])=[O:6])[CH2:3][CH2:2]1.[CH3:29][N:30]([CH3:40])[CH2:31][CH2:32][CH2:33][N:34]1[CH2:39][CH2:38][NH:37][CH2:36][CH2:35]1.C[Al](C)C>ClCCCl>[NH3:4].[CH:1]1([N:4]([CH2:18][C:19]2[O:23][C:22]([C:24]([N:37]3[CH2:38][CH2:39][N:34]([CH2:33][CH2:32][CH2:31][N:30]([CH3:29])[CH3:40])[CH2:35][CH2:36]3)=[O:25])=[N:21][N:20]=2)[S:5]([C:8]2[C:13]([CH3:14])=[CH:12][C:11]([O:15][CH3:16])=[CH:10][C:9]=2[CH3:17])(=[O:7])=[O:6])[CH2:3][CH2:2]1참가 물질
6
실험 절차
The title compound was prepared according to general procedure AT using ethyl 5-({cyclopropyl[(4-methoxy-2,6-dimethylphenyl)sulfonyl]amino}methyl)-1,3,4-oxadiazole-2-carboxylate (30 mg, 0.07 mmol), N,N-dimethyl-3-(piperazin-1-yl)propan-1-amine (27 mg, 0.16 mmol) and trimethylaluminium (2 M in toluene, 0.07 mL) in DCE (5 mL). The crude product was purified using FCC, eluting with 95:4.5:0.5 DCM:MeOH:NH3, to afford the title compound.
후처리
- customThe title compound was prepared
- customThe crude product was purified
- washeluting with 95:4.5:0.5 DCM
출처 및 근거
- ORD 기록
- ord-4f49757e164f4be083ba557bc2369b75
- 출처 데이터셋
- uspto-grants-2014_01
- 특허 번호
- US08623859B2
연결된 노트
불러오는 중…